Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - promethazine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; purified water; maize starch; lactose monohydrate; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. ,upper respiratory tract: relief of excessive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis. ,nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. ,sedation: for short term use on the advice of a doctor or pharmacist.

Singapore - English - HSA (Health Sciences Authority)

novem healthcare pte ltd - dutasteride - capsule, liquid filled - dutasteride 0.5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - paracetamol 24 mg/ml;   - oral solution - 120 mg/5ml - active: paracetamol 24 mg/ml   excipient: amaranth ammonium glycyrrhizinate citric acid glycerol macrogols as polyethylene glycol 1450 potassium sorbate propylene glycol purified water raspberry sodium benzoate sodium cyclamate sorbitol as sorbitol 70%

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - paracetamol 50 mg/ml;   - oral solution - 250 mg/5ml - active: paracetamol 50 mg/ml   excipient: amaranth ammonium glycyrrhizinate citric acid glycerol macrogols as polyethylene glycol 1450 potassium sorbate propylene glycol purified water raspberry sodium benzoate sodium cyclamate sorbitol as sorbitol 70% sunset yellow fcf

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - paracetamol 24 mg/ml;   - oral suspension - 120 mg/5ml - active: paracetamol 24 mg/ml   excipient: amaranth ammonium glycyrrhizinate carbomer hydrochloric acid nipastat raspberry saccharin sodium sodium hydroxide sorbitol water

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - paracetamol 50 mg/ml;   - oral suspension - 250 mg/5ml - active: paracetamol 50 mg/ml   excipient: ammonium glycyrrhizinate carbomer glycerol hydrochloric acid nipastat raspberry sodium cyclamate sodium hydroxide sunset yellow fcf water xanthan gum

Ireland - English - HPRA (Health Products Regulatory Authority)

pharma nord aps - glucosamine - capsule, hard - 400 milligrams per capsule - other antiinflammatory and antirheumatic agents, non-steroids; glucosamine

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.